Clinical trial
Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic…
NCT00203411 · Translational Oncology Research International, Other · Completed
Key facts
| NCT number | NCT00203411 |
|---|---|
| Title | Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer |
| Official title | A Phase II Trial to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Capecitabine (Xeloda) in Frail Patients With Untreated Metastatic Colorectal Cancer |
| Lead sponsor | Translational Oncology Research International, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine (Xeloda), Bevacizumab |
| Enrollment | 45 |
| Start date | Mar 1, 2006 |
| Primary completion | Mar 1, 2011 |
| Completion | Mar 1, 2011 |
| First posted | Sep 20, 2005 |
| Last update posted | Feb 6, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: